The evidence-based pharmacotherapy of social anxiety disorder

International Journal of Neuropsychopharmacology

Volumn 16, Issue 1, 2013, Pages 235-249

  Blanco, Carlos ^a   Bragdon, Laura B ^a   Schneier, Franklin R ^a   Liebowitz, Michael R ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

Pharmacological treatment; social anxiety disorder; social phobia

Indexed keywords

ALPRAZOLAM; ATENOLOL; BROMAZEPAM; BUSPIRONE; CITALOPRAM; CLONAZEPAM; ESCITALOPRAM; ETIRACETAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; OLANZAPINE; PAROXETINE; PHENELZINE; PREGABALIN; SERTRALINE; VENLAFAXINE;

ARTICLE; COGNITIVE THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS (TOPIC); MUTISM; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SOCIAL PHOBIA; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CONTROLLED CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; MONOAMINE OXIDASE INHIBITORS; PHOBIC DISORDERS; SEROTONIN UPTAKE INHIBITORS;

EID: 84871522140     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000119     Document Type: Article

References (107)

1. Allgulander CI (1999). Paroxetine in social anxiety disorder : a randomized placebo-controlled study. Acta Psychiatrica Scandinavica 100, 196-198.
2. Allgulander CI, Mangano R, Zhang J, Dahl AA, et al. (2004). Efficacy of venlafaxine ER in patients with social anxiety disorder : a double-blind, placebo-controlled, parallelgroup comparison with paroxetine. Human Psychopharmacology : Clinical and Experimental 9, 387-396.
3. Amies PL, Gelder MG, Shaw PM (1983). Social phobia: a comparative clinical study. British Journal of Psychiatry 142, 174-179.
4. APA (2000). Diagnostic and Statistical Manual of Mental Disorders : DSM-IV-TR. Washington DC: American Psychiatric Association.
5. Baldwin D, Bobes J, Stein DJ, Scharwaechter I, et al. (1999). Paroxetine in social phobia/social anxiety disorder : randomized, double-blind, placebo-controlled study. British Journal of Psychiatry 175, 120-126.
6. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, et al. (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders : recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 19, 567-596.
7. Bandelow B, Zohar J, Hollander E, Kasper S, et al. (2008). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World Journal of Biological Psychiatry 9, 248-312.
8. Barnett SD, Kramer ML, Casat CD, Connor KM, et al. (2002). Efficacy of olanzapine in social anxiety disorder : a pilot study. Journal of Psychopharmacology 16, 365-368.
9. Birmaher B, Axelson DA, Monk K, Kalas C, et al. (2003). Fluoxetine for the treatment of childhood anxiety disorders. Journal of the American Academy of Child & Adolescent Psychiatry 42, 415-423.
10. Birmaher B, Yelovich AK, Renaud J (1998). Pharmacologic treatment for children and adolescents with anxiety disorders. Pediatric Clinics of North America 45, 1187-1204.
11. Black B, Uhde TW (1994). Treatment of elective mutism with fluoxetine: A double-blind placebo-controlled study. Journal of the American Academy of Child & Adolescent Psychiatry 33, 1000-1006.
12. Black B, Uhde TW, Tancer ME (1992). Fluoxetine for the treatment of social phobia. Journal of Clinical Psychopharmacology 12, 293-295.
13. Blanco C, Heimberg RG, Schneier FR, Fresco DM, et al. (2010a). A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Archives of General Psychiatry 67, 286-295.
14. Blanco C, Okuda M, Markowitz JC, Liu SM, et al. (2010b). The epidemiology of chronic major depressive disorder and dysthymic disorder : results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry 71, 1645-1656.
15. Blanco C, Olfson M, Okuda M, Nunes EV, et al. (2008). Generalizability of clinical trials for alcohol dependence to community samples. Drug and Alcohol Dependence 98, 123-128.
16. Blanco C, Raza MS, Schneier FR, Liebowitz MR (2003a). The evidence-based pharmacological treatment of social anxiety disorder. International Journal of Neuropsychopharmacology 6, 427-442.
17. Blanco C, Schneier FR, Schmidt AB, Blanco-Jerez CR, et al. (2003b). Pharmacological treatment of social anxiety disorder : a meta-analysis. Depression and Anxiety 18, 29-40.
18. Blomhoff S, Haug TT, Hellstrom K, Holme I, et al. (2001). Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. British Journal of Psychiatry 179, 23-30.
19. Bridge JA, Iyengar S, Salary CB, Barbe RP, et al. (2007). Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment. Journal of the American Medical Association 297, 1683-1696.
20. Clark D, Agras WS (1991). The assessment and treatment of performance anxiety in musicians. American Journal of Psychiatry 148, 598-605.
21. Clark DM, Ehlers A, McManus F, Hackmann A, et al. (2003). Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. Journal of Consulting and Clinical Psychology 71, 1058-1067.
22. Davidson JR, Foa EB, Huppert JD, Keefe FJ, et al. (2004a). Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry 61, 1005-1013.
23. Davidson JR, Potts N, Richichi E, Krishnan R, et al. (1993). Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology 13, 423-428.
24. Davidson JR, Yaryura-Tobias J, DuPont R, Stallings L, et al. (2004b). Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology 24, 118-125.
25. Dummit ES, Klein RG, Asche B, Martin J, et al. (1996). Fluoxetine treatment of children with selective mutism: An open trial. Journal of the American Academy of Child & Adolescent Psychiatry 35, 615-621.
26. Fairbanks JM, Pine DS, Tancer NK, Dummit ES, et al. (1997). Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. Journal of Child and Adolescent Psychopharmacology 7, 17-29.
27. Fedoroff IC, Taylor S (2001). Psychological and pharmacological treatments of social phobia: a metaanalysis. Journal of Clinical Psychopharmacology 21, 311-323.
28. Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R (2011). Efficacy of pregabalin in generalized social anxiety disorder : results of a double-blind, placebo-controlled, fixed-dose study. International Clinical Psychopharmacology 26, 213-220.
29. Fleiss JL (1994). Measures of effect size for categorical data. In : Cooper H, Hedges L (Eds), The Handbook of Research Synthesis (pp. 245-260). New York, NY: Russell Sage Foundation.
30. Furmark T, Appel L, Michelgard A, Wahlstedt K, et al. (2005). Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biological Psychiatry 58, 132-142.
31. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, et al. (1991). Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Archives of General Psychiatry, 48, 938-945.
32. Gibbons R, Hur K, Bhaumik DK, Mann JJ (2006). The relationship between antidepressant prescription rates and rate of early adolescent suicide. American Journal of Psychiatry 163, 1898-1904.
33. Golwyn DH, Sevlie CP (1999). Phenelzine treatment of selective mutism in four prepubertal children. Journal of Child and Adolescent Psychopharmacology 9, 109-113.
34. Glesser LJ, Olkin I (1994). Stochastically dependent effect sizes. In : Cooper H, Hedges L (Eds), The Handbook of Research Synthesis (pp. 339-356). New York, NY: Russell Sage Foundation.
35. Gould RA, Buckminister S, Pollack MH, Otto MW, et al. (1997). Cognitive-behavioral and pharmacological treatments of social phobia: a meta-analysis. Clinical Psychology: Science and Practice 4, 291-306.
36. Graae F, Milner J, Rizzotto L, Klein RG (1994). Clonazepam in childhood anxiety disorders. Journal of the American Academy of Children & Adolescent Psychiatry 33, 372-376.
37. Grant BF, Hasin DS, Blanco C, Stinson FS, et al. (2005). The epidemiology of social anxiety disorder in the United States : results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry 66, 1351-1361.
38. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, et al. (2008). A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biological Psychiatry 63, 544-549.
39. Hedges DW, Brown BL, Shwalb DA, Godfrey K, et al. (2007). The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder : a meta-analysis of double-blind, placebo-controlled trials. Journal of Psychopharmacology 21, 102-111.
40. Hedges LV, Olkin I (1985). Statistical Methods for Meta-Analysis. Orlando, FL: Academic Press.
41. Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, et al. (1998). Cognitive-behavioral group therapy vs phenelzine therapy for social phobia. Archives of General Psychiatry 55, 1133-1141.
42. Hofmann SG, Meuret AE, Smits JA, Simon NM, et al. (2006). Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Archives of General Psychiatry 63, 298-304.
43. Kasper S, Stein DJ, Loft H, Nil R (2005). Escitalopram in the treatment of social anxiety disorder : randomised, placebo-controlled, flexible-dosage study. British Journal of Psychiatry 186, 222-226.
44. Katschnig H, Stein MB, Buller R (1997). Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience 247, 71-80.
45. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, et al. (1995). Sertraline for social phobia: a double-blind, placebo-controlled cross over study. American Journal of Psychiatry 152, 1368-1371.
46. Kessler RC, Berglund P, Demler O, Jin R, et al. (2005a). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 62, 593-602.
47. Kessler RC, McGonagle KA, Zhao S, Nelson CB, et al. (1994). Lifetime and 12 month prevalence of DSM III-R psychiatric disorders in the United States. Archives of General Psychiatry 51, 8-19.
48. Kobak KA, Griest JH, Jefferson JW, Katzelnick DJ (2002). Fluoxetine in social phobia: a double-blind placebo controlled pilot study. Journal of Clinical Psychopharmacology 22, 257-262.
49. Kutcher SP, Reiter S, Gardner DM, Klein RG (1992). The pharmacotherapy of anxiety disorders in children and adolescents. Psychiatric Clinics of North America 15, 41.
50. Lader M, Stender K, Burger V, Nil R (2004). Efficacy and tolerability of escitalopram in 12-and 24-week treatment of social anxiety disorder : randomised, double-blind, placebo-controlled, fixed-dose study. Depression and Anxiety 19, 241-248.
51. Lepola U, Bergtholdt B, St Lambert J, Davy KL, et al. (2004). Controlled-release paroxetine in the treatment of patients with social anxiety disorder. Journal of Clinical Psychiatry 65, 222-229.
52. Liebowitz MR (1987). Social Phobia. Modern Problems of Pharmacopsychiatry 22, 141-173.
53. Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, et al. (2003). Efficacy of sertraline in severe generalized social anxiety disorder : results of a double-blind, placebocontrolled study. Journal of Clinical Psychiatry 64, 785-792.
54. Liebowitz MR, Gelenberg AJ, Munjack D (2005a). Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry 62, 190-198.
55. Liebowitz MR, Heimberg RG, Schneier FR, Hope DA, et al. (1999). Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depression and Anxiety 10, 89-98.
56. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G (2005b). A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. Journal of Clinical Psychiatry 66, 238-247.
57. Liebowitz MR, Schneier FR, Campeas R, Hollander E, et al. (1992). Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Archives of General Psychiatry 49, 290-300.
58. Liebowitz MR, Stein MB, Tancer M, Carpenter D, et al. (2002). A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Journal of Clinical Psychiatry 63, 66-74.
59. Marks IM (1970). The classification of phobic disorders. British Journal of Psychiatry 116, 377-386.
60. Montgomery SA, Nil R, Durr-Pal N, Loft H, et al. (2005). A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. Journal of Clinical Psychiatry 66, 1270-1278.
61. Muehlbacher M, Nickel MK, Nickel C, Kettler C, et al. (2005). Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 25, 580-583.
62. Munjack DJ, Baltazar PL, Bohn PB, Cabe DD, et al. (1990). Clonazepam in the treatment of social phobia: a pilot study. Journal of Clinical Psychiatry 51 (Suppl.), 35-53.
63. Noyes R, Moroz G, Davidson J, Liebowitz MR, et al. (1997). Moclobemide in social phobia: a controlled dose-response. Journal of Clinical Psychopharmacology 17, 247-254.
64. Ontiveros, JA (2008). Double-blind controlled study with clonazepam and placebo in social anxiety disorder. Salud Mental 31, 299-306.
65. Öst LG (1987). Age of onset in different phobias. Journal of Abnormal Psychology 96, 223-229.
66. Pande AC, Davidson RT, Jefferson JW, Janney CA, et al. (1999). Treatment of social phobia with gabapentine: a placebo controlled study. Journal of Clinical Psychopharmacology 19, 341-348.
67. Potts NLS, Davidson JRT (1995). Pharmacological treatments: literature review. In : Heimberg RG, Liebowitz MR, Hope DA, Schneier FR (Eds), Social Phobia : Diagnosis, Assessment and Treatment (pp. 334-365). New York: Guilford.
68. Rickels K, Mangano R, Khan A (2004). A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. Journal of Clinical Psychopharmacology 24, 488-496.
69. Rynn MA, Siqueland L, Rickels K (2001). Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. American Journal of Psychiatry 158, 2008-2014.
70. Schneier FR, Blanco C, Campeas R, Lewis-Fernandez R, et al. (2003). Citalopram treatment of social anxiety disorder and comorbid major depression. Depression and Anxiety 17, 191-196.
71. Schneier FR, Chin SJ, Hollander E, Liebowitz MR (1992a). Fluoxetine in social phobia. Journal of Clinical Psychopharmacology 12, 62-64.
72. Schneier FR, Goetz D, Campeas R, Marshall R, et al. (1998). A placebo-controlled trial of moclobemide in social phobia. British Journal of Psychiatry 172, 70-77.
73. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, et al. (1992b). Social phobia: comorbidity and morbidity in an epidemiological sample. Archives of General Psychiatry 49, 282-288.
74. Schneier FR, Saoud JB (1993). Buspirone in social phobia. Journal of Clinical Psychopharmacology 13, 251-256.
75. Schutters SI, van Megen HJ, van Veen JF, Denys DA, et al. (2010). Mirtazapine in generalized social anxiety disorder : a randomized, double-blind, placebo-controlled study. International Journal of Clinical Psychopharmacology 25, 302-304.
76. Seedat S, Stein MB (2004). Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. Journal of Clinical Psychiatry 65, 244-248.
77. Simeon JG, Ferguson HB, Knott V, Roberts N, et al. (1992). Clinical, cognitive and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. Journal of the American Academy of Children & Adolescent Psychiatry 31, 29-33.
78. Simon NM, Korbly NB, Worthington JJ, Kinrys G, et al. (2002). Citalopram for social anxiety disorder : an openlabel pilot study in refractory and nonrefractory patients. CNS Spectrums 7, 655-657.
79. Simpson HB, Schneier FR, Campeas RB, Marshall RD, et al. (1998). Imipramine in the treatment of social phobia. Journal of Clinical Psychopharmacology 18, 132-135.
80. Stein DJ, Cameron A, Amrein R, Montgomery SA (2002a). Moclobemide is effective and well tolerated in the longterm pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. International Clinical Psychopharmacology 17, 161-170.
81. Stein DJ, Stein MB, Pitts CD, Kumar R, et al. (2002b). Predictors of response to pharmacotherapy in social anxiety disorder, an analysis of 3 placebo-controlled paroxetine trial. Journal of Clinical Psychiatry 63, 152-155.
82. Stein DJ, Versiani M, Hair T, Kumar R (2002c). Efficacy of paroxetine for relapse prevention in social anxiety disorder : a 24-week study. Archives of General Psychiatry 59, 1111-1118.
83. Stein MB, Fyer AJ, Davidson JRT, Pollack MH, et al. (1999). Fluvoxamine treatment of social phobia (social anxiety disorder) : a double-blind placebo-controlled study. American Journal of Psychiatry, 156, 756-760.
84. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, et al. (1998). Paroxetine treatment of generalized social phobia (social anxiety disorder) : a randomized, double-blind, placebocontrolled study. Journal of the American Medical Association 280, 708-713.
85. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, et al. (2005). Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder : a 6-month randomized controlled trial. Psychopharmacology 177, 280-288.
86. Stein MB, Sareen J, Hami S, Chao J (2001). Pindolol potentiation of paroxitine for generalized social phobia. A double-blind, placebo-controlled, cross-over study. American Journal of Psychiatry 158, 1725-1727.
87. Sternbach H (1990). Fluoxetine treatment of social phobia. Journal of Clinical Psychopharmacology 10, 230-231.
88. Turner SM, Beidel DC, Jacob RG (1994). Social phobia: a comparison of behavior therapy and atenolol. Journal of Consulting Clinical Psychology 62, 350-358.
89. van Ameringen M, Mancini C, Farvolden P, Oakman J (2000). Drugs in development for social anxiety disorder : more to social anxiety than meets SSRI. Expert Opinion on Investigational Drugs 9, 2215-2231.
90. van Ameringen M, Mancini C, Oakman J, Walker J, et al. (2007). Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. Journal of Clinical Psychiatry 68, 288-295.
91. van Ameringen M, Mancini C, Streiner DL (1993). Fluoxetine efficacy in social phobia. Journal of Clinical Psychiatry 54, 27-32.
92. van Ameringen MA, Lane RM, Walker JR, Bowen RC, et al. (2001). Sertraline treatment of generalized social phobia: a 20-week double-blind, placebo-controlled study. American Journal of Psychiatry, 158, 275-281.
93. van Ameringen M, Mancini C, Wilson C (1996). Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. Journal of Affective Disorders 39, 115-121.
94. van der Linden GJH, Stein DJ, van Balkom A (2000). The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder : a meta-analysis of randomized controlled trials. International Clinical Psychopharmacology 15(Suppl.), S15-S23.
95. van Vliet IM, den Boer JA, Westenberg GA, Ho Pian KL (1997). Clinical effects of buspirone in social phobia: a double-blind, placebo-controlled study. Journal of Clinical Psychiatry 58, 164-168.
96. van Vliet IM, den Boer JA, Westenberg HGM (1994). Psychopharmacological treatment of social phobia: a double blind controlled study with fluvoxamine. Psychopharmacology 115, 128-134.
97. van Vliet IM, Westenberg HG, Herman G, Den Boer JA (1993). MAO inhibitors in panic disorder : clinical effects of treatment with brofaromine: A double blind placebo controlled study. Psychopharmacology 112, 483-489.
98. Versiani M, Amrein R, Montgomery SA (1997a). Social phobia: long-term treatment outcome and prediction of response-a moclobemide study. International Clinical Psychopharmacology 12, 239-254.
99. Versiani M, Nardia AE, Figueira I., Mendlowicz M, et al. (1997b). Double-blind placebo controlled trials with bromazepam. Jornal Brasileiro de Psiquiatria 46, 167-171.
100. Versiani M, Nardi AE, Mundim FD, Alves AB, et al. (1992). Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. British Journal of Psychiatry 161, 353-360.
101. Wagner KD (2003). Paroxetine treatment of mood and anxiety disorders in children and adolescents. Psychopharmacology Bulletin 37(Suppl.), 167-175.
102. Walker JR, Van Ameringen MA, Swinson R, Bowen RC, et al. (2000). Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. Journal of Clinical Psychopharmacology 20, 636-644.
103. Westenberg HG, Stein DJ, Yang H, Li D, et al. (2004). A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology 24, 49-55.
104. Williams TP, Miller BD (2003). Pharmacologic management of anxiety disorders in children and adolescents. Current Opinion in Pediatrics 15, 483-490.
105. Wolff FM (1986). Meta-Analysis : Quantitative Methods for Research Synthesis. Beverly Hills, CA: Sage.
106. Zhang W, Connor KM, Davidson JR (2005). Levetiracetam in social phobia: a placebo controlled pilot study. Journal of Psychopharmacology 19, 551-553.
107. Zitrin CM, Klein DF, Woerner MG, Ross DC (1983). Treatment of phobias: a comparison of imipramine hydrochloride and placebo. Archives of General Psychiatry 40, 125-138.